动力学(音乐)
CD8型
细胞毒性T细胞
生物
免疫疗法
癌症研究
癌症免疫疗法
免疫学
免疫系统
遗传学
心理学
教育学
体外
作者
Housaiyin Li,Dan Paul Zandberg,Aditi Kulkarni,Simion I. Chiosea,Patricia M. Santos,Brian Robert Isett,Marion Joy,Gabriel Sica,Kevin J. Contrera,Curtis M. Tatsuoka,Matthias Brand,Umamaheswar Duvvuri,Seungwon Kim,Mark W. Kubik,Shaum Sridharan,Fei Tu,Jie Chen,Tullia Carmela Bruno,Dario A.A. Vignali,Anthony Richard Cillo
出处
期刊:Cancer Cell
[Cell Press]
日期:2025-03-13
卷期号:43 (4): 757-775.e8
被引量:102
标识
DOI:10.1016/j.ccell.2025.02.026
摘要
We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Combination therapies promote higher pathologic response rates versus monotherapy, and major pathologic response is associated with better survival. To address whether successful immune checkpoint inhibitor (ICI) regimens act through similar or distinct pathways, we robustly and longitudinally characterize transcriptional and proteomic dynamics of CD8 + tumor-infiltrating lymphocytes (TILs) in a clonal manner. Anti-PD-1+LAG-3 reprograms CD8 + TIL with type-I interferon response and exhaustion gene programs into effector memory and resident memory (T EM /T RM ). In contrast, anti-PD-1+CTLA-4 activates and expands pre-existing T EM /T RM CD8 + TIL, but does not rejuvenate exhausted phenotypes into T effector cells. Anti-PD-1+LAG-3, but not anti-PD-1+CTLA-4, induces widespread TCR sharing among the different transcriptional states, as well as increased TCR diversity in responding patients. Our data suggest doublet regimen-specific transcriptional and clonal dynamics of tumor-reactive CD8 + T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI